The strange case of Dr HDL and Mr HDL: Does a NO's story illuminate the mystery of HDL's dark side uncovered by Dr HDL's drug targeting CETP?

Medical Hypotheses

Volumn 69, Issue 4, 2007, Pages 752-757

  Duriez, Patrick ^a,b,c   Bordet, Régis ^a   Berthelot, Pascal ^a  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN; NITRIC OXIDE; PLACEBO; RAMIPRIL; SCAVENGER RECEPTOR BI; TORCETRAPIB;

ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG SAFETY; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; OXIDATION; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN INTERACTION;

EID: 34547860877     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.01.059     Document Type: Article

References (43)

1. Pocok Nicola, 4th December 2006, Pfizer halts clinical trials of torcetrapib due to patients safety concerns.
2. Sikorski J.A. Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease. J Med Chem 49 (2006) 1-22
3. Editorial. Cholesterol: the good, the bad, and the stopped trials. The Lancet 2006;368: 2034.
4. Lewis G.F. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr Opin Cardiol 21 (2006) 345-352
5. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
6. Brousseau M.E., Diffenderfer M.R., Millar J.S., Nartsupha C., Asztalos B.F., Welty F.K., et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscl Thromb Vas Biol 25 (2005) 1057-1064
7. Mineo C., Deguchi H., Griffin J.H., and Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ Res 98 (2006) 1352-1364
8. Calabresi L., Gomaraschi M., and Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscl Thromb Vas Biol 23 (2003) 1724-1731
9. Napoli C., de Nigris F., Williams-Ignarro S., Pignalosa O., Sica V., and Ignarro L.J. Nitric oxide and atherosclerosis: an update. Nitric Oxide 15 (2006) 265-279
10. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 7 (2001) 853-857
11. Spieker L.E., Sudano I., Hurlimann D., Lerch P.G., Lang M.G., Binggeli C., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002) 1399-1402
12. Bisoendial R.J., Hovingh G.K., Levels J.H., Lerch P.G., Andresen I., Hayden M.R., et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107 (2003) 2944-2948
13. Ou J., Ou Z., Jones D.W., Holzhauer S., Hatoum O.A., Ackerman A.W., et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107 (2003) 2337-2341
14. Drew B.G., Fidge N.H., Gallon-Beaumier G., Kemp B.E., and Kingwell B.A. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA 101 (2004) 6999-7004
15. Briand O., Martin-Nizard F., David-Dufilho M., Six I., Lestavel S., Brunet A., et al. Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release. Biochim Biophys Acta 1683 (2004) 69-77
16. Duverger N., Viglietta C., Berthou L., Emmanuel F., Tailleux A., Parmentier-Nihoul L., et al. Transgenic rabbits expressing human apolipoprotein A-I in the liver. Arterioscl Thromb Vas Biol 16 (1996) 1424-1429
17. Lebuffe G., Boullier A., Tailleux A., Delfly B., Dupuis B., Fruchart J.C., et al. Endothelial derived vasorelaxation is impaired in human APO A-I transgenic rabbits. Biochem Biophys Res Commun 241 (1997) 205-211
18. Duverger N., Kruth H., Emmanuel F., Caillaud J.M., Viglietta C., Castro G., et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 94 (1996) 13-17
19. Mackness M., Boullier A., Hennuyer N., Mackness B., Hall M., Tailleux A., et al. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun 269 (2000) 232-236 Erratum in: Biochem Biophys Res Commun 270 (2000), p. 676
20. Boullier A., Hennuyer N., Tailleux A., Furman C., Duverger N., Caillaud J.M., et al. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia. Clin Sci (Lond) 100 (2001) 343-355
21. Mineo C., Yuhanna I.S., Quon M.J., and Shaul P.W. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 278 (2003) 9142-9149
22. Nofer J.R., van der Giet M., Tolle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113 (2004) 569-581
23. Collet X., Tall A.R., Serajuddin H., Guendouzi K., Royer L., Oliveira H., et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res 40 (1999) 1185-1193
24. Fraley A.E., and Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 17 (2006) 502-509
25. Shao B., Oda M.N., Vaisar T., Oram J.F., and Heinecke J.W. Pathways for oxidation of high-density lipoprotein in human cardiovascular disease. Curr Opin Mol Ther 3 (2006) 198-205
26. Packard C.J., Third J.L., Shepherd J., Lorimer A.R., Morgan H.G., and Lawrie T.D. Low density lipoprotein metabolism in a family of familial hypercholesterolemic patients. Metabolism 25 (1976) 995-1006
27. Hussein O., Frydman G., Frim H., and Aviram M. Reduced susceptibility of low density lipoprotein to lipid peroxidation after cholestyramine treatment in heterozygous familial hypercholesterolemic children. Pathophysiology 8 (2001) 21-28
28. Shao B., Oda M.N., Bergt C., Fu X., Green P.S., Brot N., et al. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem 281 (2006) 9001-9004
29. Panzenbock U., Kritharides L., Raftery M., Rye K.A., and Stocker R. Oxidation of methionine residues to methionine sulfoxides does not decrease potential antiatherogenic properties of apolipoprotein A-I. J Biol Chem 275 (2000) 19536-19544
30. Pankhurst G., Wang X.L., Wilcken D.E., Baernthaler G., Panzenbock U., Raftery M., et al. Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein. J Lipid Res 44 (2003) 349-355
31. Casas J.P., Cavalleri G.L., Bautista L.E., Smeeth L., Humphries S.E., and Hingorani A.D. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol 164 (2006) 921-935
32. Zintzaras E., Kitsios G., and Stefanidis I. Endothelial NO synthase gene polymorphisms and hypertension: a meta-analysis. Hypertension 48 (2006) 700-710
33. Violi F., Marino R., Milite M.T., and Loffredo L. Nitric oxide and its role in lipid peroxidation. Diabetes Metab Res 15 (1999) 283-288
34. Davidson M.H., McKenney J.M., Shear C.L., and Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 48 (2006) 1774-1781
35. Hermann M., Flammer A., and Luscher T.F. Nitric oxide in hypertension. J Clin Hypertens (Greenwich) 8 (2006) 17-29
36. Zhong S., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J.D., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996) 2917-2923
37. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med 342 (2000) 145-153
38. Levkau B., Hermann S., Theilmeier G., van der Giet M., Chun J., Schober O., et al. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation 110 (2004) 3355-3359
39. Theilmeier G., Schmidt C., Herrmann J., Keul P., Schafers M., Herrgott I., et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114 (2006) 1403-1409
40. Spieker L.E., and Luscher T.F. Protection of endothelial function. Handb Exp Pharmacol 171 (2005) 619-644
41. Hu R.M., Chuang M.Y., Prins B., Kashyap M.L., Frank H.J., Pedram A., et al. High density lipoproteins stimulate the production and secretion of endothelin-1 from cultured bovine aortic endothelial cells. J Clin Invest 93 (1994) 1056-1062
42. Martin-Nizard F., Sqalli-Houssaini H., Walters-Laporte E., Boullier A., Fruchart J.C., and Duriez P. Oxidized high-density lipoproteins modulate endothelin secretion by adult bovine aortic endothelial cells. J Cardiovasc Risk 2 (1995) 263-267
43. Davenport A.P., and Maguire J.J. Endothelin Handb Exp Pharmacol 176 (2006) 295-329